Please ensure Javascript is enabled for purposes of website accessibility
Accessibility Menu
Anavex Life Sciences Stock Quote

Anavex Life Sciences (NASDAQ: AVXL)

$3.80
(-6.6%)
-$0.27
Price as of April 18, 2024, 4:00 p.m. ET

Anavex Life Sciences Return vs. S&P

1 Year 5 Year 5 Year Annualized Since IPO
AVXL -53.60% +31.49% +5.62% +5,600%
S&P +20.62% +72.50% +11.51% +289%

Anavex Life Sciences Company Info

Anavex Life Sciences Corp. is a clinical stage biopharmaceutical company, which engages in the development of different therapeutics for the treatment of neurodegenerative and neurodevelopmental diseases. Its lead compound, ANAVEX2-73, is being developed to treat Alzheimer's and Parkinson's disease and central nervous system diseases, including Rett syndrome. The company was founded by Harvey Lalach and Athanasios Skarpelos on January 23, 2004 and is headquartered in New York, NY.

News & Analysis

Valuation

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.